FGF19 increased metabolic rate in vivo and fatty acid oxidation in hepatocytes in vitro.

<p>Welchol-feeding reduced plasma FGF15 levels in DIO mice treated with or without FGFR4 ASO (n = 8–9/group; A). Subcutaneous infusion of recombinant FGF19 to mice at 100 ng/kg/day raised the plasma FGF19 levels similar to the FGF15 levels observed in FGFR4 ASO treated mice, which was diminished 3 days post-infusion (n = 8/group; B). Neither whole body VO₂ nor heart production rate showed difference between two groups before infusion (C). The infusion of FGF19 caused increases in both VO₂ (D) and heat production rate (E) as compared to the pre-infusion baseline values, which were diminished with the termination of infusion. (F) FGF19 also increased fatty acid oxidation rate in <i>in vitro</i> mouse primary hepatocytes when they were treated with vehicle, 1.0 mM AICAR (as a positive control) or 0.5 ng/ml FGF19 (n = 5/group). Data are expressed as mean ± SEM. *<i>P</i><0.05 and **<i>P</i><0.01 vs. saline group.